pre-IPO PHARMA

COMPANY OVERVIEW

Eccogene is a clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally. The company focuses on discovery and development of translational medicine in metabolic and immune-related diseases.


LOCATION

  • Shanghai, , China

  • THERAPEUTIC AREAS

  • Liver Disease
  • Metabolic Disorders

  • WEBSITE

    https://eccogene.com/


    CAREER WEBSITE

    https://eccogene.com/pages_39/


    SOCIAL MEDIA


    INVESTORS

    delos-capital huagai-capital med-fine-capital oriza-seed sinopharm-capital tf-capital tsing-song-capital


    PRESS RELEASES


    Jun 20, 2023

    Type 2 Diabetes Market to Grow Rapidly, Predicts DelveInsight | Key Companies Active in the Domain - Eli Lilly and Company, Regor, AstraZeneca, Eccogene, Pfizer, Novo Nordisk, Novartis, Amgen, MediciNova


    Jun 11, 2023

    Eccogene Raises CNY 180 Million in Series B Equity Financing, Propelling its Pipeline of Treatments for Metabolic Diseases


    Nov 3, 2022

    Eccogene Announces US IND Approval for GLP-1 Receptor Agonist ECC5004


    Aug 1, 2022

    Eccogene Announces US IND Approval for THRβ agonist ECC4703


    Jul 28, 2021

    Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia


    For More Press Releases


    Google Analytics Alternative